perpetaty	
It is made available under a CC-B	4.0 International license

1	TITLE: A Randomized, Double-blind, Placebo-controlled Crossover Pilot Study of the Effect
2	of Metformin on Airway Glucose in COPD: The Metformin and Airway Glucose In COPD
3	(MAGIC) Trial
4	
5	Authors' full names: Eva Fiorenzo <sup>1</sup> , * John S. Tregoning <sup>2</sup> ,* Isaac Fahidi <sup>1</sup> , Michael R. Edwards <sup>1</sup> ,
6	Tata Kebadze <sup>1</sup> , Patrick Mallia <sup>1</sup> , Sebastian L. Johnston <sup>1</sup> , Hugo A. Farne <sup>1</sup> .
7	
8	Authors' affiliation(s):
9	
10	<sup>1.</sup> National Heart and Lung Institute, Imperial College London
11	<sup>2.</sup> Department of Infectious Disease, Imperial College London
12	* Contributed equally.
13	
14	Corresponding author details:
15	Name: Hugo Farne
16	Email: h.farne@imperial.ac.uk
17	Twitter account name (optional): @HugoResp
18	
19	ClinicalTrials.gov Identifier: NCT03651895

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 21 SUMMARY AT A GLANCE

- 22 Elevated airway glucose is associated with bacterial infection in chronic obstructive
- 23 pulmonary disease (COPD) exacerbations. We tested whether metformin, a drug used to
- 24 treat diabetes, reduced airway glucose in patients with COPD. Recruitment/retention
- 25 difficulties led to an underpowered study, which observed no difference between
- 26 metformin and placebo on airway glucose.
- 27

### 28 ABSTRACT

# 29 Background and Objective

30 Patients with COPD have elevated levels of airway glucose. This may increase the risk of

31 bacterial infection leading to exacerbation and disease progression. We aimed to test

32 whether treating COPD patients with metformin, an oral hypoglycaemic used in diabetes,

33 reduced airway glucose.

34

#### 35 Methods

36 In this randomized, double-blind, placebo-controlled crossover pilot study, we assigned 37 patients with COPD to two 3-month periods of treatment with 1g metformin or placebo 38 twice daily, followed by the alternate treatment after a 2-week washout period. Patients 39 were required to be free of infection, antibiotic or oral steroid treatment in the 8 weeks 40 prior to enrolment. The following were collected at baseline and monthly thereafter: 41 sputum (lower airways sample), nasal/upper airway lining fluid samples using synthetic 42 absorptive matrix (SAM), spirometry, and St Georges Respiratory Questionnaire (SGRQ) and 43 COPD Assessment Test (CAT) scores. The primary outcome was a change in sputum glucose 44 following 3 months treatment with metformin compared to 3 months of placebo.

Δ	5
_	5

#### 46 Results

- 47 14 patients were randomised of whom 3 completed the study, mainly due to withdrawals
- 48 for exacerbations (8/11 withdrawals). In the n=4 patients who completed 3 months
- 49 metformin treatment, there were no significant changes in sputum or nasal glucose
- 50 compared to baseline. Metformin did not affect COPD symptom scores or spirometry.

51

- 52 Conclusions
- 53 Treatment with metformin in this underpowered pilot study did not significantly reduce
- 54 airway glucose in COPD. Larger studies are required to definitively evaluate this.

55

- 56 Short title:
- 57 Metformin and Airway Glucose in COPD
- 58
- 59 **Keywords:**
- 60 Chronic Obstructive Pulmonary Disease, COPD, Exacerbations, Metformin, Glucose,
- 61 **Randomized Controlled Trial**

### 63 INTRODUCTION

64

65 Chronic obstructive pulmonary disease (COPD) affects an estimated 400 million people globally.<sup>(1)</sup> As well as chronic respiratory symptoms, patients with COPD suffer from 66 67 episodes of acutely increased symptoms called exacerbations. These can be triggered by 68 viral infections, bacterial infections and pollution, with bacteria detected in 50-60% of 69 exacerbations. Bacterial infection of the lower airways is also associated with airway 70 inflammation, disease progression and mortality.<sup>(2)</sup> Exacerbations with bacterial infection 71 may require antibiotics, yet with antibiotic resistance a growing problem, there is a need for 72 alternative treatments. One therapeutic target is airway glucose; increased glucose levels 73 have been observed in the nasal lavage and sputum of stable COPD patients with further 74 increases during viral/bacterial COPD exacerbations.<sup>(3)</sup> In primary human airway epithelia 75 models, lower levels of airway glucose impaired *Pseudomonas aeruginosa* growth in vitro.<sup>(4)</sup> 76 Furthermore, in mice, hyperglycaemia promoted *P. aeruginosa* and *Staphylococcus aureus* growth in the airways.<sup>(4, 5)</sup> This suggests that levels of airway glucose affect microorganism 77 78 growth and survival. It may also explain why human bronchial epithelial cells increase 79 glucose uptake in the presence of cytokines or pro-inflammatory mediators; the 80 subsequently reduced airway glucose levels may prevent infection.<sup>(6)</sup>

81

A potential approach to modulating airway glucose is with existing oral hypoglycaemic drugs, developed and licensed for the treatment of diabetes. Metformin is one such drug and has been safely used in patients with COPD and diabetes without causing hypoglycaemia.<sup>(7)</sup> In patients with co-morbid COPD and diabetes, metformin treatment is associated with a lower risk of COPD-related hospitalisation and death, particularly after 2 years use, and

more so than other hypoglycaemic agents including insulin.<sup>(8-11)</sup> A 24% reduced risk of COPD
exacerbation has been reported following up to 180 days metformin use<sup>(12)</sup> as well as a 28%
and 37% reduced risk of inpatient visits with COPD after 91-180 days or 181-365 days
metformin use respectively.<sup>(13)</sup>

91

92 The mechanism by which metformin reduces COPD exacerbations remains unclear. One 93 study found that 6 months of metformin treatment did not improve spirometry or alter 94 exhaled nitric oxide, despite being associated with significant changes in symptom scores.<sup>(14)</sup> 95 Furthermore, few studies have examined the effects of metformin in COPD patients without 96 diabetes. 1 month of treatment with metformin in patients with COPD admitted for an 97 exacerbation who did not have diabetes, had no impact on blood glucose (which was 98 modestly raised in both the metformin and placebo-treated groups), blood levels of the 99 inflammatory marker C-reactive protein, or scores on the COPD Assessment Test (CAT) or 100 Exacerbations of Chronic Pulmonary Disease Tool (EXACT).<sup>(15)</sup> However treatment began at 101 hospital presentation, some days after viral infection and symptom onset, and blood but not 102 airway glucose levels were measured. We therefore undertook a pilot trial to determine 103 whether metformin altered airway glucose in COPD and to assess the feasibility of 104 conducting a full-scale trial of the efficacy of metformin prophylaxis in reducing COPD 105 exacerbations.

### 107 **METHODS**

108

- 109 Human/Animal Ethics Approval Declaration:
- 110 IRAS Number: 247421
- 111 Westminster Research Ethics Committee reference: 19/LO/0633

112

### 113 Study Design

- 114 The Metformin and Airway Glucose In COPD (MAGIC) trial was a double-blinded,
- 115 randomised, placebo-controlled cross-over trial in COPD. Recruitment began 17 May 2022
- and ended 01 June 2023. Participants were randomised to metformin or placebo for 3
- 117 months, followed by a 2-week washout period before crossing over treatment arms. The
- 118 participants attended a baseline visit followed by monthly visits until the third month of
- 119 treatment was completed. This was repeated after crossing over. At these visits, symptoms,
- 120 quality of life (QOL) and spirometry were assessed, and sputum and nasal synthetic
- 121 absorptive matrix (SAMs) samples collected.

122

#### 123 Participants

124 Patients aged 40-85 years with a clinical diagnosis of COPD confirmed on spirometry (post-

bronchodilator FEV<sub>1</sub>/FVC <70%) and a smoking history of at least 15 pack years were eligible

126 for the study. Exclusion criteria included a diagnosis of diabetes (previously or on screening

- 127 bloods), treatment with metformin, contraindications to metformin (e.g. previous allergic
- reaction to metformin, body mass index <18.5kg/m<sup>2</sup>), and a history of infection, antibiotic
- 129 and/or oral corticosteroid use in the previous 8 weeks. See supplementary material for full
- 130 inclusion and exclusion criteria. Written consent was obtained prior to participation.

131

# 132 Intervention, Randomisation and Masking

133 The study drugs were supplied by Sharp Clinical Services (Powys, UK), who produced visually 134 identical metformin and placebo tablets with the same packaging, differentiated only by a 135 unique pack ID. Eligible subjects were randomly assigned to either metformin or placebo 136 twice daily in a 1:1 ratio, according to a sequential randomisation list generated by a 137 statistician working independently of the trial that was encoded in the study database and 138 concealed up to allocation. Subjects and study investigators were blinded to treatment 139 allocation from randomisation until database lock. Treatment identity was concealed by 140 using placebo identical in packaging, labelling, schedule of administration, appearance, taste 141 and odour to metformin. Metformin was dosed at 500mg twice daily for one week to check 142 tolerability, increasing to 1g twice daily thereafter for the remainder of the 3 months. 143 Patients were considered compliant if ≥80% of investigational medicinal product (IMP) was 144 taken. 145

### 146 Outcomes

The primary outcome was change in sputum glucose following 3 months' treatment with metformin. Glucose was measured from sputum plugs using a commercial assay, the Amplex Red Glucose Assay Kit (Thermo Fisher Scientific, UK). Secondary outcomes included glucose concentrations in nasal SAM strips, COPD Assessment Test (CAT) and St George's Respiratory Questionnaire (SGRQ) scores, and forced expiratory volume in 1 second (FEV<sub>1</sub>).

## 153 Statistical Analysis

- 154 A sample size calculation indicated that 30 subjects were required to detect a reduction of
- 155 30% in airway glucose, based on the observation of similar reductions in airway glucose
- 156 following metformin treatment in mice,<sup>(16)</sup> at 90% power using a two-sided test at the 5%
- 157 significance level. This was grossed up to 40 subjects to account for withdrawals.
- 158
- 159 Data were analysed using GraphPad Prism 9 (GraphPad Software, USA). Continuous
- 160 variables are presented as medians and interquartile ranges, with the Mann-Whitney U test
- 161 used to analyse between groups and Wilcoxon signed-rank test for paired analyses.
- 162 Differences were considered statistically significant at p<0.05. All p values are two sided.

#### 164 **RESULTS**

165

166	Between 17 May 2022 and 01 June 2023, 14 participants were enrolled. 11 were
167	subsequently withdrawn spread evenly across the metformin and placebo treatment arms,
168	8 due to lower respiratory tract infections (Figure 1A). 3 subjects completed 3 months of
169	both metformin and placebo; 8 volunteers completed 3 months of a single arm (4 per arm;
170	Figure 1B). In total, there were 16 sets of samples following 1 month's treatment of either
171	placebo or metformin (8 and 8 respectively); 12 from subjects who completed 1 month in
172	the study and a further 4 from subjects who crossed over and completed 1 month in the
173	other treatment arm). The trial was ended following expiry of the study drug on 31 May
174	2023.
175	

Figure 1. Outline of participation in MAGIC study. Consort diagram (A). Timelines of
individual participants of study (B).

178

There was no significant change in the primary outcome, sputum glucose following 3 months treatment with metformin (median sputum glucose 68.92 (IQR 16.3 to 131.1)  $\mu$ M, either compared to baseline 5.3 (IQR 0.02 to 18)  $\mu$ M (p=0.13; n=3) or 3 months placebo (median sputum glucose 12.2 (IQR 10 to 13)  $\mu$ M. Furthermore, there was no change in sputum or nasal glucose with metformin treatment at any timepoint from baseline to 3 months (Figures 2A-B), including when only analysing patients who completed 3 months of either arm of treatment (Figures 2C-D). We then analysed the change in sputum and nasal

glucose after 1 month's treatment compared to baseline and found no significant change 186 (Figures 2E-F). 187

188

189	Figure 2. Effect of metformin on glucose in upper and lower airways. Volunteers with
190	COPD were assigned to either active or placebo with a washout period before switching.
191	Glucose levels were measured in sputum (A, C, E) samples and synthetic absorptive matrices
192	(SAM) collected from the nose (B, D, F). Glucose levels over the time course of the study for
193	all participants measured (A, B); levels in individuals who complete a full 3-month
194	participation (C, D). Comparison of glucose levels at baseline (V1/V5) and one month later
195	(V2/V6). At baseline N=9 participants in active, N=10 in placebo, n=4 participants finished a
196	3-month course of either metformin or placebo. Symbols represent individual participants
197	and lines medians. Statistical analysis was performed by Mann-Whitney test (A-D) and
198	Wilcoxon signed-rank test (E, F).
199	
200	
201	We additionally evaluated whether metformin affected airway function or symptoms of
202	COPD, assessed by the CAT and SGRQ questionnaires. There were no significant differences
203	in any measurement at baseline between the two arms (Figure 3A), and no difference after
204	1 month of treatment compared to baseline or between placebo and metformin treatment
205	(Figures 3B-F).

206

207	Figure 3. Metformin had no impact on measures of airway function at one month.
208	Volunteers with COPD were assigned to either active or placebo with a washout period
209	before switching. Measurements of airway function and symptoms were taken at visit 1 (A).
210	Airway function and symptoms were compared between initial visit 1 (V1) and Visit 2 (V2) of
211	each arm for FEV1 (B), FVC (C), PEF (D), CAT (E) and SGRQ (F). n ≥ 9. Symbols represent
212	individual participants and lines medians. Statistical analysis was performed by Wilcoxon
213	signed-rank test.
214	

of

215

#### 216 DISCUSSION

217

218 This pilot study adds to the literature on metformin in COPD by showing for the first time

219 that up to 3 months of metformin treatment does not affect glucose levels in upper (nasal)

220 or lower (sputum) airways samples, albeit in small numbers of patients. If born out in larger

221 prospective studies, this would suggest that metformin does not reduce COPD

222 exacerbations by modulating airway glucose. It may be that metformin does not reduce

223 exacerbations at all; the reduced rate of COPD exacerbations seen in patients with comorbid

224 diabetes on metformin<sup>(8-11)</sup> is currently an association and not known to be causal.

225 Furthermore, a comparison of airway glucose in patients with only COPD not on metformin

226 against those with COPD and type II diabetes on metformin has not been made. Like other

227 studies, we failed to see any impact of metformin on FEV<sub>1</sub> or FVC,<sup>(14, 17)</sup> even though high

228 airway glucose levels are associated with airway hyperresponsiveness.<sup>(18)</sup>

229 The main limitation of our study is the small sample size, due to a combination of under-

230 recruitment and a high number of withdrawals. Study recruitment was delayed due to the

231 COVID-19 pandemic and limited by the expiry date of the IMP when the study resumed, 232 hence only 14 out of a target 40 patients were recruited. We subsequently had a high drop-233 out rate owing primarily to the exclusion of patients who developed a lower respiratory 234 tract infection (8 of the 11 withdrawals). These were excluded on the basis that both lower 235 respiratory tract infections and the oral steroids often used to treat them (alongside 236 antibiotics) are known to alter airways glucose and could therefore confound the results. 237 The inevitable consequence, however, in a population of patients who suffer frequent 238 exacerbations (particularly in the autumn and winter when most of the subjects were 239 enrolled) was a high number of withdrawals. Future studies could consider including these 240 participants and performing subgroup analyses on samples from non-infective timepoints. 241 However, even with our small numbers, there was no trend towards a difference in airway 242 glucose with metformin treatment. 243 The sputum results may have been affected by the poor quality of samples with low cell 244 counts and high cell death, likely due to immediate freezing of samples after collection. The 245 same would not be applicable to the nasal SAM samples, although these may not reflect 246 sputum (lower airways) glucose as differences have previously been observed in the 247 biochemicals measured in sputum and nasal SAM samples collected at the same time.<sup>(19)</sup> 248 Outcomes of previous studies have suggested that longer periods of treatments such as 6 249 months may be required to detect statistically significant changes in patient symptoms.<sup>(14)</sup> 250 At a minimum, 91 days of oral anti-hyperglycaemic treatment has been required to reduce 251 the risk of exacerbation, although this will be affected by the frequency of exacerbations.<sup>(13)</sup> 252 However exacerbations are relatively infrequent events and for this reason we chose a 253 mechanistic outcome, airway glucose, that should change sooner. Nonetheless future

- 254 research may want to investigate levels of airway glucose in patients with COPD and
- 255 comorbid diabetes treated with metformin for various durations, to those with COPD but
- without diabetes. Similarly, a trial of an oral hypoglycaemic intervention might consider
- 257 studying a longer duration of treatment.
- 258 In summary, in this underpowered pilot study we found no effect of up to 3 months
- 259 metformin treatment on upper or lower airways glucose in COPD. Given the strong
- 260 epidemiological evidence linking metformin treatment to reduced rates of COPD
- 261 exacerbation and the growing problem of antibiotic resistance, larger interventional studies
- 262 of metformin treatment in COPD are warranted, and would ideally include analysis of a
- 263 possible mechanism (e.g. measurement of airways glucose).

# 265 Author Contributions

- 266 EF: Investigation, Writing Original Draft; IF: Investigation; MRE: Supervision; TK:
- 267 Investigation; PM: Conceptualization, Funding acquisition; JST: Conceptualization, Funding
- acquisition, Writing Original Draft; SLJ: Supervision, Conceptualization, Funding acquisition,
- 269 Writing Review & Editing; HF: Supervision, Investigation, Writing Review & Editing.

270

# 271 Acknowledgements:

272 NIHR Imperial Biomedical Research Centre (BRC) (P74536)

273

274 **Conflict of Interest:** SLJ is a shareholder and Director of Virtus Respiratory Research Ltd.

275

276 **Data Availability Statement:** Data availability on request.

277

#### 279 REFERENCES

280						
281	1.	Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I, et al. Global, regional, and				
282	nation	al prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in				
283	2019:	a systematic review and modelling analysis. Lancet Respir Med. 2022;10(5):447-58.				
284	2.	Beasley V, Joshi PV, Singanayagam A, Molyneaux PL, Johnston SL, Mallia P. Lung				
285	microl	piology and exacerbations in COPD. Int J Chron Obstruct Pulmon Dis. 2012;7:555-69.				
286	3.	Mallia P, Webber J, Gill SK, Trujillo-Torralbo MB, Calderazzo MA, Finney L, et al. Role				
287	of airway glucose in bacterial infections in patients with chronic obstructive pulmonary					
288	diseas	e. J Allergy Clin Immunol. 2018;142(3):815-23 e6.				
289	4.	Pezzulo AA, Gutierrez J, Duschner KS, McConnell KS, Taft PJ, Ernst SE, et al. Glucose				
290	depletion in the airway surface liquid is essential for sterility of the airways. PLoS One.					
291	2011;6	5(1):e16166.				
292	5.	Garnett JP, Baker EH, Naik S, Lindsay JA, Knight GM, Gill S, et al. Metformin reduces				
293	airway	glucose permeability and hyperglycaemia-induced Staphylococcus aureus load				
294	indepe	endently of effects on blood glucose. Thorax. 2013;68(9):835-45.				
295	6.	Garnett JP, Nguyen TT, Moffatt JD, Pelham ER, Kalsi KK, Baker EH, et al.				
296	Proinf	lammatory mediators disrupt glucose homeostasis in airway surface liquid. J Immunol.				
297	2012;1	189(1):373-80.				
298	7.	Hitchings AW, Archer JR, Srivastava SA, Baker EH. Safety of metformin in patients				
299	with c	hronic obstructive pulmonary disease and type 2 diabetes mellitus. COPD.				
300	2015;1	12(2):126-31.				

Ho TW, Huang CT, Tsai YJ, Lien AS, Lai F, Yu CJ. Metformin use mitigates the adverse
 prognostic effect of diabetes mellitus in chronic obstructive pulmonary disease. Respir Res.
 2019;20(1):69.

304 9. Liang Z, Yang M, Xu C, Zeng R, Dong L. Effects and safety of metformin in patients

305 with concurrent diabetes mellitus and chronic obstructive pulmonary disease: a systematic

306 review and meta-analysis. Endocr Connect. 2022;11(9).

307 10. Bishwakarma R, Lin Y, Kuo Y, Sharma G. Metformin and Health Care Utilization in

308 Patients With Coexisting COPD and Diabetes. Chest Journal. 2016;150(4).

309 11. Bishwakarma R, Zhang W, Lin YL, Kuo YF, Cardenas VJ, Sharma G. Metformin use and

310 health care utilization in patients with coexisting chronic obstructive pulmonary disease and

diabetes mellitus. Int J Chron Obstruct Pulmon Dis. 2018;13:793-800.

312 12. P.L. T, Valencia-Hernandez C, Farne H, Bloom C. Effect of metformin on reducing the

313 risk of COPD exacerbations: a UK nested case-control study. Thorax. 2023;78.

314 13. Wang MT, Lai JH, Huang YL, Kuo FC, Wang YH, Tsai CL, et al. Use of antidiabetic

315 medications and risk of chronic obstructive pulmonary disease exacerbation requiring

316 hospitalization: a disease risk score-matched nested case-control study. Respir Res.

317 2020;21(1):319.

318 14. Sexton P, Metcalf P, Kolbe J. Respiratory effects of insulin sensitisation with

319 metformin: a prospective observational study. COPD. 2014;11(2):133-42.

320 15. Hitchings AW, Lai D, Jones PW, Baker EH, Metformin in CTT. Metformin in severe

321 exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial.


322 Thorax. 2016;71(7):587-93.

323 16. Gill SK, Hui K, Farne H, Garnett JP, Baines DL, Moore LSP, et al. Increased airway
324 glucose increases airway bacterial load in hyperglycaemia. Sci Rep. 2016;6:27636.

325	17.	Kahnert K, Andreas S, Kellerer C, Lutter JI, Lucke T, Yildirim O, et al. Reduced decline
326	of lun	g diffusing capacity in COPD patients with diabetes and metformin treatment. Sci Rep.
327	2022;	12(1):1435.

- 328 18. Cazzola M, Calzetta L, Rogliani P, Lauro D, Novelli L, Page CP, et al. High glucose
- 329 enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway. Am
- 330 J Respir Cell Mol Biol. 2012;47(4):509-16.
- 331 19. Farne H, Groves HT, Gill SK, Stokes I, McCulloch S, Karoly E, et al. Comparative
- 332 Metabolomic Sampling of Upper and Lower Airways by Four Different Methods to Identify
- Biochemicals That May Support Bacterial Growth. Front Cell Infect Microbiol. 2018;8:432.

334



	Participant	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5	Visit 6	Visit 7	Visit 8
	A								
	В								





Figure 1. Outline of participation in MAGIC study. Consort diagram (A). Timelines of individual participants of study (B).



**Figure 2. Effect of metformin on glucose in Upper and lower airways.** Volunteers with COPD were assigned to either active or placebo with a washout period before switching. Glucose levels were measured in sputum (A, C, E) samples and synthetic absorptive matrices (SAM) collected from the nose (B, D, F). Glucose levels over the time course of the study for all participants measured (A, B); levels in individuals who complete a full 3-month participation (C, D). Comparison of glucose levels at baseline (V1/V5) and one month later (V2/ V6). At baseline N=9 participants in active, N=10 in placebo, n=4 participants finished a 3-month course of either metformin or placebo. Symbols represent individual participants and lines medians. Statistical analysis was performed by Mann-Whitney test (A-D) and Wilcoxon signed-rank test (E, F).




Figure 3. Metformin had no impact on measures of airway function at one month. Volunteers with COPD were assigned to either active or placebo with a washout period before switching. Measurements of airway function and symptoms were taken at visit 1 (A). Airway function and symptoms were compared between initial visit 1 (V1) and Visit 2 (V2) of each arm for FEV1 (B), FVC (C), PEF (D), CAT (E) and SGRQ (F).  $n \ge 9$ . Symbols represent individual participants and lines medians. Statistical analysis was performed by Wilcoxon signed-rank test.